Guardant Health, Inc.

Guardant Health, Inc. is a leading precision oncology company dedicated to transforming cancer care through innovative liquid biopsy technology and advanced molecular diagnostics. Founded in 2012, the company's core mission is to conquer cancer with data, providing critical insights into the disease through blood and tissue tests, real-world data, and AI analytics to help patients live longer, healthier lives. Its corporate headquarters are located in Palo Alto, California.

Guardant Health offers a comprehensive portfolio of products and services across the cancer care continuum. Key offerings include the Guardant360 suite (Liquid, CDx, and Tissue) for comprehensive genomic profiling and treatment selection in advanced-stage cancer patients. The company also provides Guardant Reveal for molecular residual disease detection and recurrence monitoring in early-stage colorectal, breast, and lung cancers, as well as therapy response monitoring. Additionally, Guardant Health developed Shield for colorectal cancer screening. The company extends its services to biopharmaceutical partners, offering research and development support.

Led by co-CEOs Helmy Eltoukhy and AmirAli Talasaz, Guardant Health continues to expand its market presence and product utility. In 2025, the company reported $982 million in revenue, representing 33% year-over-year growth, and projected 27-30% revenue growth for 2026. Recent strategic developments in 2026 include a multi-year collaboration with Nuvalent to develop companion diagnostics using the Guardant Infinity™ Platform and the launch of its Shield multi-cancer detection test in Asia through a partnership with Manulife. The company's Shield colon cancer test received FDA approval in 2024 and secured Medicare coverage by May 2025, further solidifying Guardant Health's position as a leader in precision oncology and liquid biopsy.